MannKind: Study shows inhaled insulin has similar efficacy to injections in Type 1 diabetes patients

By E. Janene Geiss

Philadelphia, April 19 - MannKind Corp. announced Wednesday results from a phase 2 clinical study of inhaled insulin in people with Type 1 diabetes that showed inhaled insulin has similar efficacy to injections in Type 1 diabetes patients.

The study was designed to evaluate whether inhaled insulin delivered using the MannKind Technosphere Insulin System showed similar safety and efficacy at controlling blood sugar based on dosing regimens commonly used in the every day management of diabetes, when compared to patients treated with insulin aspart (NovoLog), which is an injected rapid-acting insulin analog, according to a company news release.

"This is the first study that demonstrated that patients with Type 1 diabetes using Technosphere Insulin can achieve comparable levels of control in HbA1c as patients treated with an injected rapid-acting insulin analogue," said Peter Richardson, chief scientific officer, in the release.

In this study, the peak of the mean blood glucose values following a standardized meal test were lower for patients on Technosphere Insulin than those receiving injections of rapid-acting insulin analogue, officials said.

The study also found that patients using Technosphere Insulin did not gain weight during the study in contrast to patients using the injected rapid-acting insulin analogue. Furthermore, after 12 weeks of treatment, pulmonary function did not differ between the two patient groups, officials said.

The study included 110 patients with Type 1 diabetes on basal/prandial therapy, who where randomized to either Technosphere Insulin or the injected rapid-acting insulin analogue, Novolog, at meal time together with insulin glargine, Lantus, as basal insulin.

MannKind, based in Valencia, Calif., focuses on development and commercialization of therapeutic products for diseases such as diabetes and cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.